US 12,239,674 B2
Lactobacillus rhamnosus LRH05 isolate, and composition including the same and use thereof
Yung-Tsung Chen, New Taipei (TW); and Jin-Seng Lin, Tainan (TW)
Assigned to SYNBIO TECH INC., Kaohsiung (TW)
Appl. No. 17/604,960
Filed by SYNBIO TECH INC., Kaohsiung (TW)
PCT Filed Jun. 17, 2021, PCT No. PCT/IB2021/055352
§ 371(c)(1), (2) Date Oct. 19, 2021,
PCT Pub. No. WO2022/162439, PCT Pub. Date Aug. 4, 2022.
Claims priority of application No. 110103124 (TW), filed on Jan. 27, 2021.
Prior Publication US 2023/0107022 A1, Apr. 6, 2023
Int. Cl. A61K 35/747 (2015.01); A61K 9/00 (2006.01); A61P 1/00 (2006.01); A61P 3/00 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01)
CPC A61K 35/747 (2013.01) [A61K 9/0053 (2013.01); A61P 1/00 (2018.01); A61P 3/00 (2018.01); A61P 3/04 (2018.01); A61P 3/06 (2018.01); A61P 3/10 (2018.01); A23V 2002/00 (2013.01); A23V 2400/175 (2023.08)] 3 Claims
 
1. A method for treating diabetes mellitus, comprising administering to a subject in need thereof a pharmaceutical composition containing an isolated strain of Lactobacillus rhamnosus LRH05,
wherein the isolated strain of Lactobacillus rhamnosus LRH05 is deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH under an accession number DSM 33616.